Trends in Anticoagulation for Atrial Fibrillation in the U.S. An Analysis of the National Ambulatory Medical Care Survey Database by Rowan, Shane B. et al.
A
r
a
p
A
o
w
s
a
s
t
(
e
g
w
u
F
S
U
2
Journal of the American College of Cardiology Vol. 49, No. 14, 2007
© 2007 by the American College of Cardiology Foundation ISSN 0735-1097/07/$32.00
PHeart Rhythm Disorders
Trends in Anticoagulation for Atrial Fibrillation in the U.S.
An Analysis of the National Ambulatory Medical Care Survey Database
Shane B. Rowan, MD,* Desiree N. Bailey, BS,† Caroline E. Bublitz, MS,† Robert J. Anderson, MD*
Denver and Aurora, Colorado
Objectives The purpose of this study was to track trends in the use of anticoagulation for atrial fibrillation (AF) over the past
decade and identify predictors of use.
Background Atrial fibrillation is common and associated with significant morbidity. Previous studies suggest underuse of anti-
coagulant therapy in patients with AF.
Methods The National Ambulatory Medical Care Survey database was queried for all patient visits with a diagnosis of
AF between 1994 and 2003. Other diagnoses, other medications, and demographic, visit, geographic, and
provider characteristics were compared with the prescription of anticoagulation in predefined age and risk
groups.
Results The prevalence of the diagnosis of AF and anticoagulation for AF has increased over the last decade. Increased
age and use of rate control agents is associated with the use of anticoagulation. There is a trend toward less
anticoagulation when a rhythm control agent is used instead of a rate control agent. Anticoagulation might be
overused in a group of low-risk patients.
Conclusions From 1995 through 2002, an increase has occurred in anticoagulation for AF, especially in those at highest risk
for thromboembolic phenomena. A substantial number of patients at risk for thromboembolic events are not
anticoagulated, and further studies are needed to determine how many of these patients are candidates for
anticoagulation. Anticoagulation use has increased in nontargeted, low-risk groups in whom antiplatelet agents
are appropriate. Use of a rhythm control agent might be associated with less use of anticoagulation. (J Am Coll
Cardiol 2007;49:1561–5) © 2007 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2006.11.045p
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wtrial fibrillation (AF) is a common supraventricular ar-
hythmia that occurs in approximately 2.4 million inhabit-
nts of the U.S. Because its incidence increases with age, the
opulation over the age of 65 bears most of the burden of
F (1). Much of this burden is a result of the increased risk
f embolic stroke associated with the diagnosis. Individuals
ith nonvalvular AF have a 5% annual risk of ischemic
troke, a risk level that is 2 to 5 times greater than that of
ge-matched control subjects (2).
Anticoagulation with warfarin attenuates the ischemic
troke risk associated with AF; unfortunately, anticoagula-
ion itself carries a significant risk of bleeding complications
3,4). In an effort to help clinicians balance this risk-benefit
quation, several groups have published evidence-based
uidelines that delineate higher-risk patient populations for
hom anticoagulation is recommended and lower-risk pop-
lations for whom it might not be necessary (3,5–7). Several
rom the *Department of Medicine, University of Colorado at Denver and Health
ciences Center, Denver, Colorado; and the †Department of Family Medicine,
niversity of Colorado at Denver and Health Sciences Center, Aurora, Colorado.w
Manuscript received October 2, 2006; revised manuscript received November 20,
006, accepted November 27, 2006.revious studies have shown that, despite these guidelines,
nticoagulation might be underused in some high-risk
opulations with AF (8–13).
The present study was thus undertaken with 4 goals in
ind. First, we wanted to describe the AF patient popula-
ion between 1994 and 2003. Second, in view of ongoing
idespread emphasis regarding the need for anticoagulation
or high-risk individuals, we tested the hypothesis that the
ate of appropriate anticoagulation would be increasing over
ime. Third, a recent meta-analysis suggested that increased
orbidity in patients taking antiarrhythmic agents might be
artially due to non-anticoagulation of this group (14).
herefore, we hypothesized that patients receiving anti-
rrhythmic therapy would be treated with anticoagulation
ess often than patients receiving nodal-blockade thera-
ies. Fourth, although there is information available on
he patterns of anticoagulation of patients with AF at
ncreased risk for thromboembolic events, there is virtu-
lly no information on the use of anticoagulation in
atients with AF at lower risk for thromboembolism. We
ested the hypothesis that such low-risk individuals
ould, as suggested by current guidelines, not be treated
ith anticoagulation.
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The National Ambulatory Med-
ical Care Survey (NAMCS) da-
tabase is composed of the records
of the responses of a nationally
representative, non-federally em-
ployed group of ambulatory phy-
sicians to a standardized survey
instrument. Patient visits to se-
ected practices within a geographically defined primary
ampling unit are entered by the providing physician into
he survey form. The form includes fields for demographic
ata, up to 3 diagnoses, and up to 8 medications. Keying
nd coding of survey responses with International Classifi-
ation of Diseases, 9th Revision (ICD-9) codes and Na-
ional Drug Code numbers are performed by a central
gency with internal quality control procedures and an error
ate of 0% to 1% (15).
We combined the 1994 through 2003 NAMCS data sets
n order to produce reliable national estimates regarding the
se patterns of anticoagulant therapy among patients diag-
osed with AF. The NAMCS estimates are considered
eliable by the National Center of Health Statistics
NCHS) standards if the sample of patient visits/unit cell is
30 and the relative standard error (RSE) (standard error/
stimate) is0.30. The NAMCS patients 18 years of age or
lder with a diagnosis of AF (ICD-9  427.31) in any of
he 3 NAMCS diagnosis fields (diag1 to diag3) were
dentified for the analysis. In addition, with the NAMCS
iagnosis fields (diag1 to diag3) and medication fields
med1 to med8; gen1 to gen8), each patient’s significant
omorbidities (diabetes, hypertension, congestive heart fail-
re, and cerebrovascular accident) and usage of anticoagu-
ant therapy (warfarin), rate control agents (a composite of
eta-blocker therapy, nondihydropyridine calcium channel
locker therapy, and digitalis compounds), and antiarrhyth-
ic agents (amiodarone, sotalol, propafenone, procain-
mide, quinidine, flecainide, disopyramide, moricizine, and
ofetilide) were also identified. General demographic infor-
ation (gender, race, metropolitan statistical area, region,
hysician specialty, age category, and insurance type) were
sed to describe the entire population with AF. The same
nalysis was performed in the 18 to 64 and 65 years of age
r older populations.
nivariate and comparison analyses. Patients with AF
eceiving anticoagulant medications were categorized as
eceiving anticoagulant therapy if the patient received at
ost 1 prescription of warfarin or coumadin during the
isit. Otherwise, the patient was categorized as not receiving
nticoagulant medications. Medication and comorbidities
ere categorized similarly with the diagnosis and medica-
ion fields. Chi-square tests were then performed to deter-
ine general univariate associations among all patients with
F receiving anticoagulation medications and those not
Abbreviations
and Acronyms
AF  atrial fibrillation
NAMCS  National
Ambulatory Medical Care
Survey
NCHS  National Center
for Health Statisticseceiving anticoagulation medications and patients’ gender,
pace, metropolitan statistical area, region, physician spe-
ialty, age category, insurance type, comorbidity, and med-
cation usage. Because increasing age is considered a risk
elative Frequency ofnticoagulation by Selected Visit Characteristics
Table 1 Relative Frequency ofAnticoagulation by Selected Visit Characteristics
Visit Characteristic
Anticoagulation With Warfarin (%)
n Yes No p Value
Total patients with atrial fibrillation 40,506,313 45.66 54.34
Age category, yrs
18–59 4,545,314 34.33 65.67 0.0192*
60–75 14,794,448 45.00 55.00
76 21,166,551 48.55 51.45
Patient’s gender
Female 19,794,635 42.53 57.47 0.0890
Male 20,711,678 48.65 51.35
Patient’s race
White/non-Hispanic 36,672,549 46.37 53.63 0.2601
Other 3,833,764 38.81 61.19
Location
Metropolitan 31,304,831 45.58 54.42 0.9399
Non-metropolitan 9,201,482 45.94 54.06
Northeast 9,557,308 51.53 48.47 0.1718
Midwest 9,916,927 44.10 55.90
South 12,522,707 40.07 59.93
West 8,509,371 49.11 50.89
Provider
Cardiologist 13,467,795 46.54 53.46 0.7009
Other 27,038,518 45.22 54.78
Patient’s insurance
Private 8,259,928 38.37 61.63 0.0188
Public 29,451,917 48.63 51.37
Other 2,794,468 35.86 64.14
Other diagnosis
Diabetes
Yes 2,624,169 37.25 62.75 0.2142
No 37,882,144 46.24 53.76
Congestive heart failure
Yes 5,963,331 50.17 49.83 0.3003
No 34,542,982 44.88 55.12
Hypertension
Yes 8,366,979 52.72 47.28 0.0647
No 32,139,334 43.82 56.18
Ischemic cerebrovascular event
Yes† 1,236,976 70.42 29.58 0.0325
No 39,269,337 44.88 55.12
Any comorbidity
Yes 16,162,670 50.83 49.17 0.0276
No 24,343,643 42.23 57.77
Therapy with
Any rate agent
Yes 21,733,522 56.29 43.71 0.001*
No 18,772,791 33.35 66.65
Any rhythm agent
Yes 5,018,028 44.12 55.88 0.6875
No 35,488,285 45.87 54.13
p  0.01. †Unreliable estimate by National Center for Health Statistics standards. Results are
reliminary.
n  weighted number of patient visits with a diagnosis of atrial fibrillation.
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April 10, 2007:1561–5 Anticoagulation in AFactor for thromboembolism with AF, similar chi-square
nalyses were performed among patients with AF 18 to 64
ears of age without known congestive heart failure, previ-
us cerebrovascular event, hypertension, or diabetes melli-
us. Because sample sizes for this analysis were small,
eliability of the estimates could not be made; therefore, the
esults of this analysis should be considered preliminary.
Owing to multiple testing, statistical significant associa-
ions are determined at the alpha level of 0.01.
To compare the use of anticoagulant medications among
atients with AF receiving antiarrhythmic therapies with
hose receiving rate control therapies, a 2-sample t test was
erformed. For this analysis, patients with AF who received
oth rate and rhythm control medications were eliminated
rom the analysis.
ime trend analysis. Time trend analyses were performed
o determine whether the odds of receiving anticoagulant
edication increased each year among all AF patients.
imple logistic regression analyses were performed for
nticoagulation usage (yes, no) adjusted for survey year as a
ontinuous variable. To determine whether the odds of
nticoagulation usage are increasing differently among AF
atients by age, similar stratified simple logistic analyses
ere also performed among patients 18 to 59 years, 60 to 75
ears, and 76 years or older segregated by the presence or
bsence of a comorbid condition known to be associated
ith increased thromboembolic risk (known congestive
eart failure, previous cerebrovascular event, hypertension,
r diabetes mellitus). In addition, descriptive statistics (per-
ent, weighted estimates) for each age strata were also
ncluded in terms of 3 equal time periods (1995 to 1997,
998 to 2000, and 2001 to 2003).
ercentage of Patients With Atrial Fibrillation Taking Anticoagulati
Table 2 Percentage of Patients With Atrial Fibrillation Taking A
1995–1997 1998–20
Total % Anticoagulated Total % A
Ages 18–59 yrs
Total 1,073,378 24.08%* 1,871,404
With comorbidity 291,620† 28.40%* 700,351*
Without comorbidity 781,758 22.46%* 1,171,053
Ages 60–75 yrs
Total 4,117,539 49.22% 4,476,365
With comorbidity 1,548,309 43.31% 1,730,889
Without comorbidity 2,569,230 52.78% 2,745,476
Ages 76 yrs
Total 4,627,721 36.02% 6,324,152
With comorbidity 2,051,851 37.98% 2,509,379
Without comorbidity 2,575,870 34.45% 3,814,773
All patients
Total 9,818,638 40.25% 12,671,921
With comorbidity 3,891,780 39.38% 4,940,619
Without comorbidity 5,926,858 40.82% 7,731,302
he odds ratio (OR) represents anticoagulant usage adjusted for survey years as a continuous varia
p  0.05.
CI  confidence interval; Total  weighted number of patient visits with a diagnosis of atrial fibrillatioBecause NAMCS patient visits are sampled with a
ultistage probability sample design, all analyses were
erformed with SUDAAN 9.1 software (Research Triangle
nstitute, Research Triangle Park, North Carolina) and the
AMCS patient weight. All estimates were tested for
eliability by NCHS standards. Unreliable estimates are
oted in the text and tables.
esults
uring the 1994 to 2003 time period, approximately 40.5
illion AF patient visits occurred. Of these patients, 18.0
illion (45.6%) received anticoagulant therapy. Among all
atients with AF, age and use of “rate control” agents were
ssociated with receiving anticoagulant therapy. A higher
roportion of patients 60 years of age or older received
nticoagulant therapy compared with patients 18 to 59 years
f age. A higher percentage of patients with AF receiving
rate control” agents received anticoagulant therapies. Pa-
ients’ gender, race, metropolitan status, geographical area,
ype of treating physician, insurance type, individual comor-
ities, and use of a rhythm agent were not significantly
ssociated with anticoagulant use (Table 1).
The frequency with which AF was listed as a diagnosis
ncreased over the period between 1994 and 1997 and 2001
o 2003 (Table 2). The overall frequency of anticoagulation
lso increased from 40.3% of all patients with AF between
994 and 1997 to 49.1% during the 2001 to 2003 time
eriod. The relative frequency of anticoagulation—
omparing the same time periods—increased by 80% in the
8- to 59-year-old population, decreased by 8% in the 60-
o 75-year-old population, and increased by 45% in the 76
nd older population. Logistic regression analyses deter-
Time Period and Age Group
agulation by Time Period and Age Group
2000–2002
OR 95% CI p Valuegulated Total % Anticoagulated
% 1,600,532 43.40% 1.16 (1.00–1.35) 0.0436†
* 449,053† 58.27%*
* 1,151,479 37.60%*
% 6,200,544 45.25% 1.00 (0.91–1.09) 0.9247
% 1,993,137 46.18%
% 4,207,407 44.81%
% 10,214,678 52.34% 1.11 (1.02–1.19) 0.0097†
% 4,888,081 58.90%
% 5,326,597 46.31%
% 18,015,754 49.10% 1.07 (1.01–1.13) 0.0181†
% 7,330,271 55.40%
% 10,685,483 44.78%
reliable estimates by National Center for Health Statistics standards. Results are preliminary.on by
ntico
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nticoa
32.44
52.18
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Anticoagulation in AF April 10, 2007:1561–5ined an overall yearly increase of 7% in the odds of
eceiving anticoagulant therapy among all patients with AF
uring this time period. As noted in Table 2, the use of
nticoagulation over time was somewhat selective inasmuch
s it was greater in patients with comorbid conditions
ssociated with thromboembolic phenomena than in those
ithout these conditions.
We next examined the frequency of anticoagulation use
n patients treated exclusively with “rate control” agents
beta-blocker therapy, calcium channel blocker therapy, and
igoxin) compared with patients treated exclusively with
rhythm control” agents (any antiarrhythmic). There was a
rend toward the use of anticoagulant therapy more com-
only in patients taking rate control agents than in those
aking rhythm control agents (58.4% vs. 47.1%, respectively,
 0.0596).
Finally, we examined the frequency of anticoagulation in
atients with AF whom most practice guidelines would
lassify as at relatively low risk for a thromboembolic event:
ndividuals under 65 years of age without known congestive
eart failure, previous cerebrovascular event, hypertension,
r diabetes mellitus. Interestingly, 30.1% of this low-risk
roup of 5,037,812 patient visits was anticoagulated. There
ere no demographic, geographic, or therapeutic character-
stics that were associated with the use of anticoagulant
herapy in this group. Interestingly, having a cardiologist as
provider was associated with a more than 2-fold chance of
eceiving anticoagulant therapy in these low-risk patients;
owever, results of this analysis are considered preliminary,
ecause estimates are unreliable by NCHS standards owing
o relatively small sample sizes (Table 3).
iscussion
ur analysis of the NAMCS database provides several
nteresting insights into the use of anticoagulation for AF in
ontemporary general medical practice in the U.S. First, the
requency of diagnosis of AF continues to increase. This
nding correlates well with other studies that have docu-
ented a similar rise (1).
Second, adherence with guidelines for anticoagulation of
atients at relatively high risk for thromboembolic phenom-
na seems to be improving. Our univariate analyses suggests
hat there are various factors, such as insurance status,
omorbid conditions (congestive heart failure, hypertension,
nd diabetes mellitus), and the use of a “rate control” agent,
hat are associated with use of anticoagulation. It is note-
orthy, however, that the factors associated with “appro-
riate” use of anticoagulation in patients with AF might be
omplex. The factors we identified differed from those
escribed previously by Stafford et al. (16) in which a history
f stroke, residence outside of the South, age 80, and
reatment by a cardiologist or internist were significantly
orrelated with “appropriate” use of anticoagulation. Also,
any patients with AF at risk for thromboembolic eventshat qualify for anticoagulant therapy are not receiving it. aowever, a significant proportion of these patients might
ot be reasonably good candidates for anticoagulation, and
stimates as to the “target” goal for anticoagulation of
elected high-risk populations with AF remains to be better
efined. Our results might therefore underestimate the
ppropriate use of anticoagulation in patients with AF.
Third, it seems that recent increases in the use of
nticoagulant therapy have occurred primarily in the young-
st (age 18 to 59 years) and oldest (age 76 years and older)
ith comorbid conditions predisposing to thromboembolic
vents. The trend for increasing anticoagulation in the
ldest populations with cormorbid conditions is encourag-
ng, because previous research suggests possible underuse of
nticoagulation in this population (10,16).
Fourth, in patients receiving antiarrhythmic therapy,
here is a suggestion that anticoagulation is particularly
nderused. Although this trend did not quite reach statis-
ical significance, it is of particular concern, given recent
ata that patients taking antiarrhythmic therapy continue to
ave a significant risk of embolic events (17). The attitude
hat Brodsky et al. (18) demonstrated a decade ago—that
atients with paroxysmal AF may be treated with aspirin
elative Frequency of Anticoagulation in Patientsge 18 to 64 Yrs by Selected Visi Characteristics
Table 3 Relative Frequency of Anticoagulation in PatientsAge 18 to 64 Yrs by Selected Visit Characteristics
Visit Characteristic
Anticoagulation With Warfarin (%)
n Yes No p Value
Patient’s gender
Female* 1,303,849 30.86 69.14 0.8915
Male 3,733,963 29.80 70.20
Patient’s race
White/non-Hispanic 4,442,923 31.15 68.85 0.3734
Other* 594,889 22.09 77.91
Location
Metropolitan 4,059,233 32.57 67.43 0.2237
Non-metropolitan* 978,579 19.75 80.25
Northeast* 1,129,095 38.34 61.66 0.6347
Midwest* 1,381,887 27.33 72.67
South* 1,709,157 25.39 74.61
West* 817,673 33.10 66.90
Provider
Cardiologist 2,396,086 44.82 55.18 0.0002†
Other* 2,641,726 16.70 83.30
Patient’s insurance
Private 3,158,519 33.93 66.07 0.0724
Public* 910,087 34.38 65.62
Other* 969,206 13.49 86.51
Therapy with
Any rate agent
Yes 2,407,791 35.77 64.23 0.1285
No 2,630,021 24.86 75.14
Any rhythm agent
Yes* 1,054,709 49.63 50.37 0.0150
No 3,983,103 24.90 75.10
Unreliable estimate by National Center for Health Statistics standards. Results are prelimi-
ary. †p  0.01.
n  weighted number of patient visits with a diagnosis of atrial fibrillation.lone—likely persists today. It seems likely that physicians
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April 10, 2007:1561–5 Anticoagulation in AFelieve, despite evidence to the contrary, that antiarrhyth-
ic therapy effectively prevents recurrent AF in all patients
nd thus obviates the need for anticoagulation (19).
Finally, there might be potential for overuse of anticoag-
lation in younger patients. Although the guidelines vary
omewhat in age cutoffs and risk factors, it is clear that many
f the patients under the age of 65 with no clear risk factors
hat we identified could, by current guidelines, have been
reated with aspirin alone (5,6). The use of anticoagulation
otentially exposes this population to an unnecessary risk of
emorrhagic complications. The phenomenon of “spread”
f a therapy from targeted populations to other populations
or whom the therapy is not indicated or even contraindi-
ated has been observed previously in patients with heart
ailure (20). It should be noted, however, that our studies do
ot address the issue of anticoagulation occurring in the
ontext of either pharmacologic or electrical cardioversion of
F. It is possible that younger, lower-risk individuals with
F either seek or are referred to cardiologists and are
nticoagulated in association with attempts at cardioversion.
learly, further studies are indicated as to the reasons for
nticoagulant use in “lower-risk” individuals with AF.
onclusions
he use of anticoagulation for AF has slowly increased in
he last decade. This increase in use seems to have occurred
t both ends of the age spectrum. Although this increased
se is encouraging, there are 2 important caveats. First,
any patients are still not receiving anticoagulation. Pa-
ients receiving therapy meant to maintain sinus rhythm
ight be at a higher risk for underuse of anticoagulation
han those taking “rate control” therapies. Second, the
ncrease in use of anticoagulation seems to have been
articularly notable among patients who might not benefit
rom this therapy.
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